SAFB2

Summary

SAFB2 (scaffold attachment factor B2, HGNC:21605) is a protein-coding gene on chromosome 19p13.3, encoding Scaffold attachment factor B2 (Q14151). Binds to scaffold/matrix attachment region (S/MAR) DNA.

The protein encoded by this gene, along with its paralog (scaffold attachment factor B1), is a repressor of estrogen receptor alpha. The encoded protein binds scaffold/matrix attachment region (S/MAR) DNA and is involved in cell cycle regulation, apoptosis, differentiation, the stress response, and regulation of immune genes.

Source: NCBI Gene 9667 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 179 total
• MANE Select transcript: NM_014649

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21605
Approved symbol	SAFB2
Name	scaffold attachment factor B2
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0138
Ensembl gene	ENSG00000130254
Ensembl biotype	protein_coding
OMIM	608066
Entrez	9667

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 5 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay

ENST00000252542, ENST00000585449, ENST00000587802, ENST00000589925, ENST00000590000, ENST00000590262, ENST00000591101, ENST00000591120, ENST00000591123, ENST00000591310, ENST00000592599, ENST00000850599, ENST00000850600, ENST00000912090, ENST00000912091

RefSeq mRNA: 1 — MANE Select: NM_014649 NM_014649

CCDS: CCDS32879

Canonical transcript exons

ENST00000252542 — 21 exons

Exon	Start	End
ENSE00001611192	5598793	5598884
ENSE00001677871	5595361	5595497
ENSE00001698179	5611120	5611630
ENSE00001708115	5593891	5594178
ENSE00001751671	5612540	5612567
ENSE00001762209	5616132	5616335
ENSE00002914462	5622530	5622776
ENSE00003458607	5591748	5591793
ENSE00003486358	5604787	5604936
ENSE00003568249	5600130	5600260
ENSE00003571373	5587701	5587767
ENSE00003594754	5613465	5613527
ENSE00003616267	5592747	5592887
ENSE00003640527	5616422	5616486
ENSE00003645600	5609995	5610095
ENSE00003662102	5587868	5587980
ENSE00003670599	5621309	5621396
ENSE00003670721	5610639	5610688
ENSE00003676030	5604583	5604695
ENSE00003693059	5590278	5590408
ENSE00004282295	5586999	5587399

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 98.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 66.4845 / max 2231.2215, expressed in 1825 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178549	66.4845	1825

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.74	gold quality
cerebellar hemisphere	UBERON:0002245	98.58	gold quality
adenohypophysis	UBERON:0002196	98.55	gold quality
cerebellar cortex	UBERON:0002129	98.53	gold quality
right uterine tube	UBERON:0001302	98.49	gold quality
left ovary	UBERON:0002119	98.24	gold quality
pituitary gland	UBERON:0000007	98.23	gold quality
right ovary	UBERON:0002118	98.21	gold quality
sural nerve	UBERON:0015488	98.20	gold quality
endocervix	UBERON:0000458	97.99	gold quality
cerebellum	UBERON:0002037	97.77	gold quality
metanephros cortex	UBERON:0010533	97.66	gold quality
body of uterus	UBERON:0009853	97.62	gold quality
right lobe of thyroid gland	UBERON:0001119	97.50	gold quality
left lobe of thyroid gland	UBERON:0001120	97.47	gold quality
nerve	UBERON:0001021	97.45	gold quality
tibial nerve	UBERON:0001323	97.45	gold quality
lower esophagus mucosa	UBERON:0035834	97.35	gold quality
right frontal lobe	UBERON:0002810	97.26	gold quality
left testis	UBERON:0004533	97.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.04	gold quality
right testis	UBERON:0004534	96.95	gold quality
thyroid gland	UBERON:0002046	96.93	gold quality
ectocervix	UBERON:0012249	96.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.89	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.86	gold quality
lower esophagus	UBERON:0013473	96.85	gold quality
apex of heart	UBERON:0002098	96.75	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.73	gold quality
left adrenal gland cortex	UBERON:0035825	96.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting SAFB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-1207-5P	99.49	69.11	2983

Literature-anchored findings (GeneRIF, showing 9)

• REVIEW: possibility that SAFB1 and SAFB2 are novel breast tumor suppressor genes, and how they might function in this role, are discussed (PMID:14587024)
• SAFB2 is not likely to be causative of the hereditary breast cancer syndrome in west Swedish breast cancer families (PMID:19077293)
• This study shows that low SAFB protein levels predict poor prognosis of breast cancer patients, suggesting critical functions of SAFB1 and SAFB2 in breast cancer cells. (PMID:19137425)
• The enzymatic activity of SR protein kinases 1 and 1a is negatively affected by interaction with scaffold attachment factors B1 and 2. (PMID:19674106)
• Study confirms the primary role of SAFB1/SAFB2 as corepressors and also uncovers a previously unknown role for SAFB1 in the regulation of immune genes and in estrogen-mediated repression of genes. (PMID:19901029)
• Results indicate that SAFB1 and SAFB2 are crucial repressors for ERalpha dynamics in association with the nuclear matrix and that their synergistic regulation of ERalpha mobility is sufficient for inhibiting ERalpha function. (PMID:22566185)
• Single depletion of either SAFB1 or SAFB2 leads to an increase in expression of the other SAFB protein. (PMID:26273616)
• SAFB2 Enables the Processing of Suboptimal Stem-Loop Structures in Clustered Primary miRNA Transcripts. (PMID:32502422)
• SAFB2 Inhibits the Progression of Breast Cancer by Suppressing the Wnt/beta-Catenin Signaling Pathway via NFAT5. (PMID:36652182)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Safb2	ENSMUSG00000042625
rattus_norvegicus	Safb2	ENSRNOG00000049511
drosophila_melanogaster	Saf-B	FBGN0039229
caenorhabditis_elegans	phm-2	WBGENE00009314

Paralogs (2): SLTM (ENSG00000137776), SAFB (ENSG00000160633)

Protein

Protein identifiers

Scaffold attachment factor B2 — Q14151 (reviewed: Q14151)

All UniProt accessions (3): Q14151, K7EQU4, K7ERX3

UniProt curated annotations — full annotation on UniProt →

Function. Binds to scaffold/matrix attachment region (S/MAR) DNA. Can function as an estrogen receptor corepressor and can also inhibit cell proliferation.

Subunit / interactions. Interacts with SAFB/SAFB1 and SCAM1. Interacts with isoform 2 SRPK1 and inhibits its activity.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed at high levels in the CNS and at low levels in the liver. Expressed in a wide number of breast cancer cell lines.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14151-1	1	yes
Q14151-2	2

RefSeq proteins (1): NP_055464* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR003034	SAP_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034781	SAFB1_2_RBD	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR036361	SAP_dom_sf	Homologous_superfamily
IPR051738	SAF_Modulators	Family

Pfam: PF00076, PF02037

UniProt features (66 total): cross-link 22, compositionally biased region 16, modified residue 14, region of interest 6, domain 2, splice variant 2, initiator methionine 1, chain 1, short sequence motif 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9RMV	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14151-F1	55.34	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (36): 2, 54, 109, 158, 201, 207, 507, 513, 616, 787, 832, 886, 897, 903, 65, 65, 94, 188, 199, 230 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 119 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY, MARTINEZ_RB1_TARGETS_UP, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, ONKEN_UVEAL_MELANOMA_UP, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_RESPONSE_TO_STEROID_HORMONE, GOBP_RESPONSE_TO_HORMONE, GOBP_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_STEROID_HORMONE_STIMULUS

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), regulation of mRNA processing (GO:0050684), Sertoli cell differentiation (GO:0060008), regulation of androgen receptor signaling pathway (GO:0060765)

GO Molecular Function (6): RNA binding (GO:0003723), identical protein binding (GO:0042802), sequence-specific DNA binding (GO:0043565), nucleic acid binding (GO:0003676), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), nuclear body (GO:0016604), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
binding	2
cellular anatomical structure	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
mRNA processing	1
regulation of mRNA metabolic process	1
developmental process involved in reproduction	1
male gonad development	1
epithelial cell differentiation	1
androgen receptor signaling pathway	1
regulation of intracellular steroid hormone receptor signaling pathway	1
protein binding	1
DNA binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
nucleoplasm	1
intracellular membraneless organelle	1
extracellular vesicle	1

Protein interactions and networks

STRING

1028 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SAFB2	SORBS3	O60504	844
SAFB2	ESR1	P03372	827
SAFB2	ZNRF4	Q8WWF5	589
SAFB2	HNRNPU	Q00839	574
SAFB2	SRPK1	Q96SB4	567
SAFB2	DROSHA	Q9NRR4	475
SAFB2	ZNF622	Q969S3	445
SAFB2	ZNF358	Q9NW07	422
SAFB2	LBR	Q14739	417
SAFB2	ZNF823	P16415	411
SAFB2	SPEN	Q96T58	408
SAFB2	KHDRBS2	Q5VWX1	380
SAFB2	SREK1	Q8WXA9	372
SAFB2	TINCR	A0A2R8Y7D0	367
SAFB2	CELF2	O95319	362

IntAct

188 interactions, top by confidence:

A	B	Type	Score
RB1CC1	ATG13	psi-mi:“MI:0914”(association)	0.820
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
FUS	SAFB2	psi-mi:“MI:0915”(physical association)	0.550
SAFB2	ESR1	psi-mi:“MI:0407”(direct interaction)	0.540
ESR1	SAFB2	psi-mi:“MI:0915”(physical association)	0.540
SAFB2	SORBS3	psi-mi:“MI:0915”(physical association)	0.540
SAFB2	SORBS3	psi-mi:“MI:0403”(colocalization)	0.540
RPS6	IPO7	psi-mi:“MI:0914”(association)	0.530
SAFB2	DHPS	psi-mi:“MI:0914”(association)	0.530
NCBP3	SAP18	psi-mi:“MI:0914”(association)	0.530
SYNGAP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
SYNGAP1	SEC16A	psi-mi:“MI:0914”(association)	0.530
SUPT5H	POLR2D	psi-mi:“MI:0914”(association)	0.530
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
ZFP41	LRP4	psi-mi:“MI:0914”(association)	0.530
CAPN13	SFSWAP	psi-mi:“MI:0914”(association)	0.530
EZH1	EPOP	psi-mi:“MI:0914”(association)	0.530
HNRNPC	CASC3	psi-mi:“MI:0914”(association)	0.530
ELAVL2	CASC3	psi-mi:“MI:0914”(association)	0.530
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
SRSF3	CASC3	psi-mi:“MI:0914”(association)	0.530
LRRK2	DFFA	psi-mi:“MI:0914”(association)	0.530
SAFB2	SAFB2	psi-mi:“MI:0915”(physical association)	0.520
SAFB	SAFB2	psi-mi:“MI:0915”(physical association)	0.510
SAFB2	SAFB	psi-mi:“MI:0915”(physical association)	0.510
GABARAPL1	SAFB2	psi-mi:“MI:0915”(physical association)	0.500

BioGRID (278): SAFB2 (Affinity Capture-RNA), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), TP53 (Affinity Capture-Western), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), SAFB2 (Affinity Capture-MS), HNRNPUL1 (Co-fractionation), SAFB (Co-fractionation), SAFB2 (Co-fractionation)

ESM2 similar proteins: A0A0R4IZ84, A2CEZ5, A2RV70, D3YXK2, F1MJM0, O15047, O43823, O60293, O88291, O88453, P41073, P43243, P43244, P61129, P61406, P78332, P97868, Q08D57, Q14151, Q15424, Q1LY77, Q28F29, Q2HJG4, Q3TLH4, Q498L2, Q5BKZ1, Q5F3P8, Q5R452, Q5RAK6, Q5RCA4, Q5U236, Q5VK71, Q5ZJ02, Q63014, Q66HC1, Q66J90, Q7YZA2, Q7Z6E9, Q80YR5, Q86US8

Diamond homologs: A0A0D1C8Z4, A1A5R1, A2A5N3, A3LXL0, A4F5G6, A5A6M3, A5DW14, A6NFN3, A6QPR6, F1QB54, F4HT49, O04319, O13845, O35698, O43251, O93235, P0CB38, P11940, P19682, P19683, P19684, P20965, P28644, P29341, P38159, P42731, P49313, P49314, P60824, P60825, P60826, P61286, P62995, P62996, P62997, Q04836, Q08935, Q08937, Q09511, Q0VD23

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 228 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	7	17.0×	1e-05
mRNA 3’-end processing	12	15.1×	2e-09
mRNA Polyadenylation	25	14.0×	2e-19
mRNA Splicing	20	14.0×	1e-15
Processing of Capped Intron-Containing Pre-mRNA	25	13.1×	8e-19
RNA Polymerase II Transcription Termination	9	12.6×	3e-06
Transport of Mature mRNA derived from an Intron-Containing Transcript	12	11.6×	4e-08
mRNA Splicing - Minor Pathway	8	11.4×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	9	33.3×	1e-09
regulation of mRNA splicing, via spliceosome	7	30.0×	3e-07
alternative mRNA splicing, via spliceosome	6	19.5×	5e-05
RNA splicing, via transesterification reactions	6	18.1×	8e-05
activation of innate immune response	7	16.3×	3e-05
positive regulation of transcription by RNA polymerase I	5	15.7×	1e-03
mitophagy	10	15.4×	2e-07
spliceosomal complex assembly	5	14.5×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

179 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	140
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3672 predictions. Top by Δscore:

Variant	Effect	Δscore
19:5587979:CCCTT:C	acceptor_gain	1.0000
19:5587980:CCTT:C	acceptor_gain	1.0000
19:5587983:T:C	acceptor_gain	1.0000
19:5587983:T:TC	acceptor_gain	1.0000
19:5590311:AG:A	donor_gain	1.0000
19:5590311:AGCCT:A	donor_gain	1.0000
19:5590312:G:C	donor_gain	1.0000
19:5590404:TAGTG:T	acceptor_gain	1.0000
19:5590405:AGTG:A	acceptor_gain	1.0000
19:5590406:GTG:G	acceptor_gain	1.0000
19:5590407:TG:T	acceptor_gain	1.0000
19:5590407:TGCTG:T	acceptor_loss	1.0000
19:5590408:GCTGG:G	acceptor_loss	1.0000
19:5590409:C:CC	acceptor_gain	1.0000
19:5590409:C:CG	acceptor_loss	1.0000
19:5592743:TGAC:T	donor_loss	1.0000
19:5592744:GACC:G	donor_loss	1.0000
19:5592745:A:AC	donor_gain	1.0000
19:5592745:ACCT:A	donor_loss	1.0000
19:5592746:C:CC	donor_gain	1.0000
19:5592746:CCTGT:C	donor_gain	1.0000
19:5592883:CTCGT:C	acceptor_gain	1.0000
19:5592884:TCGT:T	acceptor_gain	1.0000
19:5592885:CGT:C	acceptor_gain	1.0000
19:5592885:CGTC:C	acceptor_gain	1.0000
19:5592886:GT:G	acceptor_gain	1.0000
19:5592886:GTCTG:G	acceptor_loss	1.0000
19:5592887:TC:T	acceptor_loss	1.0000
19:5592888:C:CA	acceptor_loss	1.0000
19:5592888:C:CC	acceptor_gain	1.0000

AlphaMissense

6276 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:5604794:A:T	V480E	1.000
19:5604800:A:C	I478S	1.000
19:5604800:A:G	I478T	1.000
19:5604800:A:T	I478N	1.000
19:5604815:A:G	L473P	1.000
19:5604830:A:G	L468P	1.000
19:5604841:G:C	C464W	1.000
19:5604843:A:G	C464R	1.000
19:5604875:A:T	V453D	1.000
19:5604877:G:C	F452L	1.000
19:5604877:G:T	F452L	1.000
19:5604878:A:C	F452C	1.000
19:5604878:A:G	F452S	1.000
19:5604879:A:G	F452L	1.000
19:5604881:C:A	G451V	1.000
19:5604881:C:T	G451E	1.000
19:5604882:C:G	G451R	1.000
19:5604882:C:T	G451R	1.000
19:5604885:A:C	Y450D	1.000
19:5604886:G:C	C449W	1.000
19:5604888:A:G	C449R	1.000
19:5604908:G:T	A442D	1.000
19:5604917:A:T	V439E	1.000
19:5604920:A:T	V438E	1.000
19:5604922:T:A	K437N	1.000
19:5604922:T:G	K437N	1.000
19:5604923:T:A	K437I	1.000
19:5604924:T:C	K437E	1.000
19:5604926:G:T	A436D	1.000
19:5604935:A:T	V433D	1.000

dbSNP variants (sampled 300 via entrez): RS1000080546 (19:5598571 C>G,T), RS1000187445 (19:5601743 TAAG>T), RS1000282044 (19:5607215 C>A,G,T), RS1000333940 (19:5607419 A>T), RS1000371187 (19:5622744 C>G,T), RS1000526590 (19:5592164 T>C), RS1000541540 (19:5614415 T>C), RS1000612591 (19:5619664 T>C), RS1000661968 (19:5608381 G>A), RS1000824449 (19:5600551 G>A), RS1000847161 (19:5611899 T>C), RS1000912840 (19:5614212 C>T), RS1000950257 (19:5593745 G>A,C), RS1001284647 (19:5608556 A>C,G), RS1001313008 (19:5592525 G>A,C)

Disease associations

OMIM: gene MIM:608066 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001188_1	vWF and FVIII levels	9.000000e-06
GCST003434_10	Obsessive-compulsive symptoms	7.000000e-06
GCST009844_7	Creativity	3.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007802	obsessive-compulsive symptom measurement
EFO:0010650	creativity measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Quercetin	decreases phosphorylation, increases expression	2
Valproic Acid	increases expression, affects expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
arsenite	increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
epigallocatechin gallate	affects cotreatment, increases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	affects phosphorylation	1
Catechin	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer